Assessment of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD) Prevalence in Patients With Heterozygous Familial Hypercholesterolemia (HeFH): the STEATO-FH Study
Status: Recruiting
Location: See all (3) locations...
Intervention Type: Other, Diagnostic test
Study Type: Observational
SUMMARY
The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 35
Healthy Volunteers: f
View:
• Patient aged 35 or over
• Consultation at Nantes, Rennes or Angers University Hospital during the inclusion period
• With a diagnosis of familial hypercholesterolemia defined by the presence of a genetic variant, ACMG classes 4 \& 5 on LDLR, APOB or PCSK9
• Patient not objecting to inclusion in study (no written objection)
Locations
Other Locations
France
CHU angers
NOT_YET_RECRUITING
Angers
CHU Nantes
RECRUITING
Nantes
Rennes University Hospital
NOT_YET_RECRUITING
Rennes
Contact Information
Primary
Sarra SMATI
sarra.grangeon@chu-nantes.fr
02 53 48 27 19
Time Frame
Start Date: 2025-01-30
Estimated Completion Date: 2028-01-30
Participants
Target number of participants: 200
Treatments
Study population
The study population must correspond to the research inclusion criteria. A fibroscan will be performed on each patient enrolled in the study. Each participant will also be offered a biological sample for an ancillary study.
Related Therapeutic Areas
Sponsors
Leads: Nantes University Hospital
Collaborators: University Hospital, Angers, Rennes University Hospital